MyFinsight
Home
Blog
About
Available-for-sale investments
$41,258K
(-34.64%↓ Y/Y)
Cash and cash
equivalents
$16,160K
(-6.16%↓ Y/Y)
Prepaid expenses
$518K
(-92.21%↓ Y/Y)
Other receivables
$426K
(-14.46%↓ Y/Y)
Total current assets
$58,362K
(-33.29%↓ Y/Y)
Operating lease,
right-of-use assets
$5,353K
(-5.72%↓ Y/Y)
Property and equipment,
net
$4,127K
(-8.82%↓ Y/Y)
Restricted cash
$1,495K
(-48.05%↓ Y/Y)
Financing lease,
right-of-use assets
$298K
(-66.67%↓ Y/Y)
Other assets
$190K
(187.88%↑ Y/Y)
Total assets
$69,825K
(-31.23%↓ Y/Y)
Total liabilities and
stockholders equity
$69,825K
(-31.23%↓ Y/Y)
Total stockholders'
equity
$48,594K
(-34.91%↓ Y/Y)
Total current
liabilities
$11,396K
(-26.62%↓ Y/Y)
Long-term operating lease
liability, net of current...
$9,799K
(-8.80%↓ Y/Y)
Long-term financing lease
liability, net of current...
$36K
(-94.02%↓ Y/Y)
Noncontrolling interest in
pangu biopharma...
-$194K
(-2.65%↓ Y/Y)
Total atyr pharma
stockholders equity
$48,788K
(-34.81%↓ Y/Y)
Accrued expenses
$6,690K
(-35.17%↓ Y/Y)
Accounts payable
$3,242K
(-16.46%↓ Y/Y)
Current portion of
operating lease liability
$946K
(23.02%↑ Y/Y)
Current portion of
financing lease liability
$518K
(-7.83%↓ Y/Y)
Accumulated deficit
-$627,264K
(-10.73%↓ Y/Y)
Accumulated other
comprehensive loss
-$68K
(9.33%↑ Y/Y)
Additional paid-in capital
$676,022K
(5.42%↑ Y/Y)
Common stock, 0.001 par
value per share...
$98K
(5.38%↑ Y/Y)
Back
Back
Balance Sheet
aTYR PHARMA INC (ATYR)
aTYR PHARMA INC (ATYR)
source: myfinsight.com